Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Allogene Therapeutics's enterprise value was -$112.75M on Nov 11, 2026, against $48.72M a year earlier. Over the last 5 years it ranged from -$112.75M to $1.28B, with a median of $137.03M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$112.75M | -493.8% |
| 2025 | Dec 31, 2025 | $28.63M | -33.2% |
| 2024 | Dec 31, 2024 | $42.84M | +1.6% |
| 2023 | Dec 29, 2023 | $42.14M | -84.3% |
| 2022 | Dec 30, 2022 | $268.66M | -78.7% |
| 2021 | Dec 31, 2021 | $1.26B | -50.0% |
| 2020 | Dec 31, 2020 | $2.53B | -1.5% |
| 2019 | Dec 31, 2019 | $2.56B | +477.9% |
| 2018 | Dec 31, 2018 | $443.82M | – |
See a number that looks wrong?